Drugs for Congestive Heart Failure
This article was originally published in Start Up
Executive Summary
A drug maker with a new CHF treatment will be helping to fill a serious unmet clinical need and benefiting from a huge, chronic care market. But development costs are huge and risks are high: the clinical history is lined with failed drugs. Thus, most CHF drug projects are in large companies; biotechs cluster at the pre-compound discovery end.